Lao People's Democratic Republic vs Montenegro: Access to anti-retroviral drugs, male
Lao People's Democratic Republic
61.0%
in 2024
Montenegro
61.0%
in 2024
Lao People's Democratic Republic rank
97th
Montenegro rank
97th
Access to anti-retroviral drugs, male over time
- Lao People's Democratic Republic
- Montenegro
How they compare
Lao People's Democratic Republic currently reports 61.0% against 61.0% in Montenegro, a difference of 0.0%.
Across all 24 years both countries report, Montenegro has been ahead every year.
Lao People's Democratic Republic ranks 97th and Montenegro ranks 97th of 141 countries.
Montenegro has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Lao People's Democratic Republic | Montenegro | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 5.8% | 15.0% | 9.2% | Montenegro |
| 2010s | 25.4% | 36.8% | 11.4% | Montenegro |
| 2020s | 51.4% | 56.4% | 5.0% | Montenegro |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Lao People's Democratic Republic or Montenegro?
- Lao People's Democratic Republic, at 61.0% against 61.0% in Montenegro as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Lao People's Democratic Republic and Montenegro?
- 0.0%, with Lao People's Democratic Republic ahead.
- How many years of comparable data are there for Lao People's Democratic Republic and Montenegro?
- 24 years are reported by both, from 2000 to 2024.
- How do Lao People's Democratic Republic and Montenegro rank globally for access to anti-retroviral drugs, male?
- Lao People's Democratic Republic ranks 97th and Montenegro ranks 97th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.